<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-4-2">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>

			</div>

			<div class="slide-title red two-line">
				Eltrombopag in severe aplastic anaemia: <br />dosage and administration
			</div>


			<div class="content-container">

				<table class="red">
					<tr>
						<th>Platelet count result</td>
						<th>Dose adjustment or response</td>
					</tr>
					<tr class="odd">
						<td>&lt;50×109/l following at least 2 weeks of eltrombopag</td>
						<td>Increase daily dose by 25 mg to a maximum of 75 mg/day</td>
					</tr>
					<tr>
						<td>≥200×109/l to ≤400×109/l at any time</td>
						<td>Decrease the daily dose by 25 mg<br /><br />

							Wait 2 weeks to assess the effects of this and any subsequent dose adjustments
						</td>
					</tr>
					<tr>
						<td>>400×109/l</td>
						<td>Stop eltrombopag; increase the frequency of platelet monitoring to twice weekly<br /><br />

						Once the platelet count is &lt;150×109/l, reinitiate therapy at a daily dose reduced by 25 mg

						</td>
					</tr>
					<tr>
						<td>>400×109/l after 2 weeks of therapy at lowest dose of eltrombopag</td>
						<td>Discontinue eltrombopag</td>
					</tr>
					<tr style="background: #C41230;text-align:center;height: 51px;color: #FFF;font-size: 20px;">
						<th colspan="2">The lowest possible dose of eltrombopag should be used to initiate and maintain a haematological response</th>
					</tr>
				</table>

			</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/"><span>GlaxoSmithKline. Eltrombopag tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ul>

		</div>

		<div class="information-overlay overlay">

			<header>Eltrombopag in aplastic anaemia: dosage and administration</header>
				
			<ul>
				<li><span>Dose adjustments are based upon the platelet count</span></li>
				<li><span>The lowest dose of eltrombopag should be used to establish a haematological response</span></li>
				<li><span>Haematological response requires dose titration, generally up to 150 mg and may take up to 12 weeks after starting eltrombopag</span></li>
				<li><span>Eltrombopag should be initiated at 50 mg once daily for all patients and adjusted to maintain a platelet count ≥50×109/l</span></li>
				<li><span>For severe aplastic anemia patients of East Asian ancestry or those with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B, C), eltrombopag may be initiated at a reduced dose of 25 mg once daily </span></li>
				<li><span>The dose should not exceed 150 mg per day</span></li>
				<li><span>Eltrombopag should be taken on an empty stomach (1 hour before, or 2 hours after a meal)</span></li>
				<li><span>A 4-hour interval should be allowed between eltrombopag and other medications, foods or supplements containing polyvalent cations (e.g. iron, calcium, aluminium, magnesium, selenium and zinc)</span></li>
			</ul>

		</div>

		</div>
	</div>
</div>